Table 2.
mean plasma concentration of GH, IGF1 and insulin at day 3, 10 and 30 [mean ± standard deviation (min-max)].
| GH (mIU/L) | IGF1 (ng/ml) | Insulin (mIU/L) | ||
|---|---|---|---|---|
| Day 3 | All ( n = 51) | 50 ± 41 (5–208) | 9 ± 8 (1–29) | 27 ± 46 (1–307) |
| <28 weeks GA | 42 ± 37 (11–110) | 5.8 ± 6 (1–23) | 34 ± 35 (2–131) | |
| AGA (n = 32) | 38 ± 28 (6–110) | 8 ± 8 (2–29) | 25 ± 26 (1–131) | |
| SGA (n = 19) | 70 ± 51 (5–208)** | 10 ± 7 (1–25) | 31 ± 74 (1–307) | |
| Insulin (n = 14) | 44 ± 38 (5–110) | 5 ± 7 (1–23) | 56 ± 83 (5–208) | |
| No insulin (n = 47) | 52 ± 42 (6–208) | 10 ± 8 (1–29) | 18 ± 20 (1–80) | |
| Day 10 | All ( n = 34) | 38 ± 25 (5–148) | 21 ± 12 (1–40) | 16 ± 16 (1–80) |
| <28 weeks GA | 43 ± 44 (5–148) | 11 ± 8 (1–25) | 31 ± 25 (7–80) | |
| AGA (n = 26) | 38 ± 28 (5–148) | 19 ± 12 (1–40) | 18 ± 19 (1–80) | |
| SGA (n = 8) | 38 ± 10 (23–52) | 29 ± 10 (13–39)* | 11 ± 8 (1–23) | |
| Insulin (n = 10) | 39 ± 42 (5–148) | 16 ± 8 (1–25) | 30 ± 23 (12–80)* | |
| No insulin (n = 24) | 38 ± 16 (12–75) | 24 ± 13 (1–40) | 10 ± 9 (1–36) | |
| Day 30 | All ( n = 25) | 47 ± 29 (14–144) | 26 ± 13 (1–48) | 14 ± 14 (1–61) |
| <28 weeks GA | 48 ± 26 (21–80) | 18 ± 12 (1–48) | 12 ± 6 (1–21) | |
| AGA (n = 23) | 43 ± 20 (14–82) | 25 ± 13 (1–48) | 15 ± 14 (1–61) | |
| SGA (n = 2) | (35–144) | (37–40) | (2) | |
| Insulin (n = 8) | 42 ± 27 (14–80) | 23 ± 15 (13–48) | 13 ± 5 (7–21) | |
| No insulin (n = 17) | 50 ± 32 (17–144) | 29 ± 11 (13–45) | 15 ± 16 (1–61) |
*
p < 0.05
**
p < 0.01 for comparison between AGA vs. SGA or insulin vs. no insulin groups.